A review in the Journal of Investigative Dermatology outlines why uveal melanoma remains difficult to treat — and where natural killer cell therapy may change that.
Uveal melanoma begins in the melanocytes of the eye's uveal tract — the choroid, ciliary body, and iris. According to a review published in the Journal of Investigative Dermatology, it is the most common intraocular malignancy and accounts for roughly 5% of all melanomas.
The cancer carries a distinct genetic signature. The review identifies mutations in GNAQ, GNA11, BAP1, SF3B1, and EIF1AX as the primary drivers of disease progression. Chromosomal changes matter too: the study found that monosomy 3 and gains on chromosome 8q are strongly linked to poor outcomes, while disomy 3 and 6p gains point toward a better prognosis.
Why current treatments fall short
Despite advances in localised eye treatment, the review reports that uveal melanoma remains difficult to manage once it spreads beyond the eye. Standard immunotherapy approaches that have reshaped treatment for cutaneous melanoma have shown limited effectiveness here, the authors noted, due to the tumour's distinct immune environment and genetic profile.
The case for natural killer cells
The review turns its attention to natural killer (NK) cell therapy as a potential path forward. NK cells are part of the innate immune system and can identify and destroy tumour cells without prior sensitisation, according to the authors. Researchers reported that early investigations into NK-cell-based therapies suggest they may be better suited to uveal melanoma's specific biology than existing checkpoint inhibitors.
The authors acknowledged that most NK cell research remains at preclinical or early clinical stages. Significant questions around delivery, persistence in the body, and tumour resistance still need to be resolved, the review noted.
For the albinism community, the biology of melanocytes sits close to home. People with albinism carry variants affecting melanin production — the same cellular system in which uveal melanoma originates. Research into melanocyte-related cancers, including the immune mechanisms that govern them, holds direct relevance for understanding ocular health across conditions that share this cellular foundation.
The review was published in the Journal of Investigative Dermatology.
Keywords
Core topics and entities mentioned in this summary.